Lilly 3Q

Lilly 3Q09

3Q Revenues: $5.6 billion (+7%)

3Q Earnings: $942 million (loss of $466 million in 3Q08)

YTD Revenues: $15.9 billion (+5%)

YTD Earnings: $3.4 billion (+119%)

Comments: Earnings comparisons were affected by Lilly’s 3Q08 charge of $1.5 billion to settle federal and state investigations into Zyprexa marketing practices. U.S. revenues rose 14% to $3.1 billion, while ex-U.S. figures fell 1% to $2.4 billion. In 3Q09, Zyprexa revenues rose 3% to $1.2 billion, Cymbalta rose 10% to $790 million, Humalog rose 16% to $500 million, and Almita sales grew 47% to $462 million. For the YTD, Zyprexa is flat at $3.5 billion, Cymalta is up 14% to $2.2 billion, Humalog is up 12% to $1.4 billion and Alimta is up 41% to $1.2 billion. Beseiged by generic competition, Gemzar sales fell 25% to $332 million in 3Q09 and 19% to $1.1 billion YTD. The company recognized sales and collaboration revenues of $102 million for Erbitux, which it acquired when it bought ImClone.

Read our Lilly profile in this year’s Top Companies Report!